LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Research

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J, Becerra M, Benedetti A, Burgos MV, Centis R, Chan ED, Chiang C, Cox HS, DAmbrosio L, DeRiemer K, Huy Dung N, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia M, Gandhi N, Granich R, Hollm-Delgado M, Holtz TH, Iseman M, Jarlsberg L, Keshavjee S, Kim HJ, Koh WJ, Lancaster J, Lange C, de Lange W, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin S, Mitnick CD, Narita M, ORiordan P, Pai M, Palmero D, Park S, Pasvol G, Pena J, Perez-Guzman C, Quelapio M, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin S, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand M, Tabarsi P, Tupasi T, van Altena R, Van der Walt M, Van der Werf T, Vargas M, Viiklepp P, Westenhouse J, Yew WW, Yim JJ
Download
Download
Abstract
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB.
Countries
ArgentinaBangladeshCanadaEstoniaFranceHong KongIran ItalyJapanSouth KoreaLatviaMexicoNetherlandsPeruPhilippinesRussian FederationSouth AfricaSpainTaiwan, Province of ChinaUnited KingdomUnited States of AmericaUzbekistanViet Nam
Subject Area
antibiotic resistancetuberculosisantimicrobial resistance
DOI
10.1371/journal.pmed.1001300
Published Date
28-Aug-2012
PubMed ID
22952439
Languages
English
Journal
PLOS Medicine
Volume / Issue / Pages
Volume 9, Issue 8
Issue Date
28-Aug-2012
Dimensions Badge